Sentnyl Therapeutics, Inc. Re-Launches Abstral® in the United States
Summary
Target acquisition opportunities include late stage development programs and marketed products in specialty pharmaceuticals.Due to the risk of respiratory depression, Abstral is contraindicated in the management of acute or postoperative pain including headache/migraine and in opioid non-tolerant patients.This should be considered when prescribing or dispensing Abstral in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.Please see Full Prescribing Information, with Boxed Warning Solana Beach, CA, May 01, 2016 --( PR.com )-- Sentynl Therapeutics, Inc. (“Sentynl”) announced that its commercial organizationrelaunched Abstral® in the United States.Target acquisition opportunities include late stage development programs and marketed products in specialty pharmaceuticals.Please visit http://www.sentynl.com/business-development/ for more information or contact us at bd@sentynl.com.